Opendata, web and dolomites

AptaCheck

Bioelectronic lab-on-a-chip for point-of-care detection of infectious agents

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AptaCheck project word cloud

Explore the words cloud of the AptaCheck project. It provides you a very rough idea of what is the project "AptaCheck" about.

scalable    clinically    identifications    electronic    detection    samples    600    wireless    chip    approved    time    drawbacks    chain    data    hospitals    pathogens    biochips    quality    complete    eventual    scanner    diagnosis    point    edge    platform    infections    diagnostics    turnover    adequately    obligatory    industrial    preventing    fast    industry    elisa    wifi    semi    advantage    aptachek    action    enter    strategic    optimisation    immediately    downstream    market    later    equipped    instability    antibody    communication    overcome    3bn    patients    qr    financing    15    house    biosensor    markets    automated    manufacturing    poc    drug    gastroenteritis    easily    isolated    minutes    handling    microbiological    care    detecting    accuracy    aptacheck    mover    secure    2024    74    aptamer    jobs    parallel    departments    accurate    2020    display    lower    first    beats    cumulative    special    outbreaks    versatile    approvals    revenues    skills    linked    human    infectious    flu    consolidated    8m    simplicity    disposable    groundbreaking    clinics    transfer    observation    portability    cutting    lab    clinical    reader    pcr    supply    direct   

Project "AptaCheck" data sheet

The following table provides information about the project.

Coordinator
SOLSTEN DIAGNOSTICS AS 

Organization address
address: HEDEAGER 40
city: AARHUS N
postcode: 8200
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://solsten-diag.com
 Total cost 2˙254˙187 €
 EC max contribution 1˙577˙931 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-08-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SOLSTEN DIAGNOSTICS AS DK (AARHUS N) coordinator 1˙577˙931.00

Map

 Project objective

AptaCheck is a groundbreaking platform for detecting infections pathogens in human samples: the first aptamer-based biosensor platform with lab-quality accuracy, allowing a fast, clinically accurate diagnosis. AptaCheck will overcome the drawbacks of the antibody based point-of-care (POC) devices (lower accuracy and instability). Aptacheck is equipped with a hand-held reader, which comprises a display for direct observation, a QR scanner for identifications, and WiFi for data transfer. AptaCheck beats the state of the art: - Cost: The disposable chip will cost the end user €10 - Time: Turnover-time is less than 15 minutes including sample handling - Accuracy: AptaCheck will be more reliable than ELISA and comparable to PCR - Simplicity: No special equipment or skills are needed - Portability: The hand-held reader and biochips can be used at the point of care - Communication: AptaCheck will be linked to electronic lab systems via wireless communication - Action: Patients can adequately be treated; Infectious patients can immediately be isolated preventing eventual outbreaks - Versatile: AptaCheck can easily be adapted to detection of new pathogens. We consolidated our first-mover advantage in in-house, robust, semi-automated, cutting-edge, up-scalable industrial production process for the biochips. AptaChek will be approved and deployed in clinical microbiological departments in hospitals. Later it will be deployed at clinics, drug manufacturing industry, etc. With Phase II financing, AptaCheck will enter a €3.3bn market for gastroenteritis diagnostics in 2020, and produce €74.8m in cumulative revenues for FLU and 600 new jobs in FLU and the supply chain by 2024. FLU seeks funding to complete the system optimisation for pre-clinical testing and for the obligatory clinical approvals. In parallel to this, we will secure a key strategic downstream distribution partner, and investigate new markets and applications in the diagnostics sector for the AptaCheck platform.

 Deliverables

List of deliverables.
Portfolio of communication material Other 2020-02-18 15:41:04

Take a look to the deliverables list in detail:  detailed list of AptaCheck deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "APTACHECK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "APTACHECK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

NAS (2018)

Nexilis augmentation system

Read More  

Volumizer (2018)

A natural, non-surgical, and safe facial filler which treats the root cause of facial ageing.

Read More